View an animated demonstration of the subconjunctival injection technique used in MacuSight's clinical trials

MacuSight's lead development program centers on sirolimus, a highly-potent, broad-acting compound with multiple mechanisms of action

Wet age-related macular degeneration (wet AMD) is the leading cause of permanent blindness among the elderly and the number of people affected is increasing at a rate of approximately 13% each year